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Background: Complement Factor I (CFI) is a serine protease with an important role in complement alternative
pathway regulation. Complete factor I deficiency is strongly associated with severe infections. Approximately 30
families with this deficiency have been described worldwide.
Patients and methods: We have studied five new Spanish families suffering from CFI deficiency. From 19 screened
people, 7 homozygous, 10 heterozygous and 2 healthy subjects were identified. Clinical, biochemical and genetic
descriptions are included.
Results: Molecular studies demonstrated 4 novel mutations in the screened individuals; amongst them, we
describe here the first great gene deletion reported in the CFI locus, which includes full exon 2 and part of the
large intron 1.
Conclusion: CFI deficiency is possibly an underestimated defect and the eventual existence of this deficiency
should be tested in those patients exhibiting low C3 and recurrent bacterial infections. We propose a simple
diagnostic flowchart to help clinicians in the identification and correct diagnosis of such patients.
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Diagnostic flowchartBackground
The human complement system consists of more than
35 plasma or membrane-bound proteins whose activa-
tion is tightly controlled through the action of comple-
ment inhibitors. It is involved in host defense against
infectious agents, in the removal of apoptotic cells and
immune complexes, and in the modulation of the adap-
tive immune system [1]. Complement deficiencies,
acquired or hereditary, affecting all the soluble compo-
nents and many of the membrane-anchored receptors
and regulators have been described in humans. Most of
these deficiencies are inherited as autosomal recessive* Correspondence: mlopeztrascasa.hulp@salud.madrid.org
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distribution, and reproduction in any mediumdisorders, with C1 inhibitor (C1INH) and Properdin
deficiencies being remarkable exceptions, inherited in
autosomal dominant and X-linked manners, respectively.
Acquired complement deficiency may be due to infec-
tious diseases or immune complexes-related disorders.
Genetic complement deficiencies have been described
affecting either protein function or concentration [2,3].
One of the most important complement activation
regulators is Complement Factor I (CFI), a serine pro-
tease that circulates in a zymogen-like state [4] at a con-
centration of ~35 μg/mL [5]. The CFI protein is a
heavily N-glycosylated heterodimer consisting of two
polypeptide chains linked by a single disulfide bond
[6,7]. The heavy chain (50KDa) comprises an N-terminal
region; an FI membrane attack complex (FIMAC)
domain; a CD5 like-domain or scavenger receptor
cysteine-rich (SRCR) domain; two low-density lipopro-
tein receptor (LDLr) domains; and a C-terminal regiond Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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across species [4]. The light chain (38KDa) contains the
serine protease (SP) domain with the conserved catalytic
residues [8]. The gene of this complement regulator
(CFI, OMIM*217030) comprises 13 exons localized on
chromosome 4q25 [9,10] and its deficiency is inherited
in an autosomal recessive manner.
CFI inactivates C3b by cleaving it into iC3b, C3d and
C3dg and, in an analogous way, C4b into C4c and C4d.
To properly perform its functions, CFI requires the pre-
sence of several cofactor proteins such as C4b-Binding
Protein (C4BP), Complement Factor H (CFH), Comple-
ment Receptor 1 (CR1/CD35) and Membrane Cofactor
Protein (MCP/CD46) [2]. Complete CFI deficiency leads
to the uncontrolled amplification of C3 cleavage, result-
ing in a severe secondary C3 deficiency. Consumption of
Complement Factor B (CFB) and CFH are also related
with CFI deficiency [2]. Consequently, the most fre-
quently associated pathologies to CFI deficiency are
severe infections by encapsulated microorganisms, glo-
merulonephritis and autoimmune diseases [11].
In this article we describe five new Spanish families
with complete CFI deficiency, an underestimated com-
plement defect mainly characterized by recurrent, severe
infections, low C3 and normal C4 levels in serum. The
fact that this persistent biochemical profile is shared by
other relatively infrequent complement abnormalities
leads us to propose a simple scheme to help clinicians in




Members from five unrelated Spanish families with CFI
deficiency were studied. Serum and DNA samples were
obtained under standard conditions after written informed
consent of the participants.
Patient I.1 was a 37 year old woman with a long-
standing history of recurrent rhino-conjunctivitis. At the
age of 4, she had several episodes of otitis, sinusitis and
bronchitis. At age 16, she had an episode of meningo-
coccal septicaemia with disseminated intravascular coa-
gulation (DIC) and skin complications. Later, she
suffered from an acute arthritis episode. Infections sever-
ity declined with age. Her mother (I.2), sister (I.4) and
brother (I.5) were also studied.
Patient II.1 was an 8 year old boy, the only child of
healthy parents (II.2 and II.3). He had a history of recur-
rent pneumonia, an episode of meningococcemia and
other infections such a balanitis or oral thrush.
Patient III.1 was a 6 year old boy. His parents (III.2,
III.3) and brother (III.4) were also studied. He had recur-
rent episodes of bronchitis. At the age of 5 he had a
bacteraemia episode and a meningococcal sepsis withmeningitis when he was 6. His recurrent episodes of oti-
tis made the implantation of ear tubes necessary.
Patient IV.1 was a 5 year old girl. She had recurrent
episodes of pneumonia and one episode of facial celluli-
tis. At the age of 5 she had a hypocomplementemic vas-
culitis episode. Her parents and a sister, aged 8 months,
were also studied (IV.2, IV.3 and IV.4).
Patient V.1 was a 6 year old girl with a history of
meningitis and pneumonia. At the age of 4, she began
suffering from recurrent Henoch-Schönlein purpura out-
breaks (15 in two years). Her parents (V.2 and V.3) and
her half sister (V.4) were included in the study.
Complement studies
The functional activity of the classical pathway was mea-
sured by CH-50 haemolytic assay, according to standard
procedures. C3 and C4 were measured by Nephelometry
(Dade Behring, Marburg, Germany). Ouchterlony analy-
sis: Initial screening for the qualitative estimation of the
remaining complement components was performed by
double immunodifussion with polyclonal antibodies
against most of the soluble C components (C1q, C1r,
C1s, C2, C5-C9, CFB, CFH and CFI). Serum levels of
CFH and CFI proteins were measured by standard meth-
ods [12]. Anti CFH auto antibodies (CFHA) were quan-
tified as described by Abarretegui-Garrido et al. [13].
CFB levels were determined by an in-house sandwich
ELISA of serum samples by coating the plates with a
polyclonal anti-Factor B [14]. The haemolytic assay for
C3 nephritic factor (C3NeF) was carried out following
the procedures described by Rother [15].
Western blotting
Four microliters of serum from patients and healthy
controls were separated by 8% gel electrophoresis under
non-reducing conditions, transferred to a PDVF mem-
brane and detected with polyclonal anti-CFI antibodies,
as described by Gonzalez-Rubio et al. [12].
Sequencing of genomic DNA
The 13 exons and their flanking intronic regions in the CFI
gene were amplified and sequenced using primers and con-
ditions described by Ponce-Castro et al. [16]. For mutation
nomenclature, the Ensemble accessions ENST00000394634
and ENSP00000378130 were used as reference.
Multiplex ligation-dependent probe amplification (MLPA)
In order to detect eventual deletions or insertions in the
CFI locus, copy number variation was measured with the
SALSA MLPA kit P296 aHUS (MRC-Holland, Amster-
dam, The Netherlands) following manufacturer instruc-
tions. The kit contains probes for the amplification of the
13 CFI exons, their flanking regions and several other
reference chromosomal locations. Data normalization
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data analysis software (MRC-Holland).
Long range PCR (XL-PCR)
A genomic fragment spanning approximately 9Kb
(intron 1 to intron 3) was amplified using the GeneAmp
XL PCR kit (Applied Biosystems, Madrid, Spain). Reac-
tion products were resolved in 0.7% ultrapure agarose
gels, purified with the QIAquick Gel Extraction kit (Qia-
gen) and sequenced. The sequence of the primers used





The clinically affected index cases from the five families
studied have complete deficiency of CFI protein. Two of
the relatives, III.4 and IV.4, brother and sister of III.1
and IV.1 respectively, were also completely CFI deficient,
although they had no clinical signs related with this
defect by the time the study was performed. All the CFI
homozygous deficient had very reduced or no detectable
CFI antigen in serum by ELISA and Western Blot (type I
CFI deficiency, in which protein production or secretion
is below the normal range). Their C3, CFB and CFH
levels were also diminished as a consequence of the
spontaneous activation and uncontrolled amplification
of the complement alternative pathway. In contrast, par-
tial CFI deficiency in some patients’ relatives was charac-
terized by diminished levels of CFI but normal amounts
of all other complement proteins analyzed. In all cases,
other possible causes of uncontrolled complement con-
sumption, like the presence of C3NeF or anti CFH auto
antibodies (CFHA), were ruled out. Complement profiles
are shown in Figure 1.
A genetic cause of the deficiency was found in all
families. The mutations identified in this series (sum-
marized in Table 1) behave as recessive traits, as only
homozygous carriers develop clinical symptoms.
We found 4 novel mutations causing CFI deficiency.
Among them, we describe here the first large gene dele-
tion reported in the CFI locus, which includes exon 2
and part of the very large intron 1. This deletion was
found in Family III and was characterized by MLPA.
The findings were confirmed by long range PCR (XL-
PCR), demonstrating a deletion size of approximately 5-
6Kb (c.266-?_536 + ?del) in patient III.1, his mother III.2
and his brother III.4. The resulting fragments were
resolved in 0.7% ultrapure agarose gel (Figure 2) but the
precise break points of this deletion could not be confi-
dently determined. In addition to that, patient III.2 car-
ries a second, unreported molecular change in exon 4,
c.738 A>T; p.N177I. Taking into account that patientIII.2’s serum CFI levels are reduced (23% of normal, see
Figure 1) but significantly higher than in the homozy-
gous deficient individuals and in her completely deficient
offspring (in which CFI is undetectable), the substitution
c.738 A>T is probably an unreported polymorphic var-
iant. Patient III.2’s two children inherited the exon 2
deletion but not the c.738 A>T substitution, which
implies that both changes are located in different alleles.
In any case and due to the lack of co-segregation data,
additional studies should be performed to confirm or
disprove the polymorphic nature of the c.738 A>T
change.
A novel mutation in exon 4 (c.559 C>T) was identi-
fied in families IV and V. The C>T transition converted
residue R187 into a premature termination codon. No
consanguinity was reported affecting families IV and V,
but their close geographic origin hints at a founder effect
as a probable cause for the co-occurrence of this muta-
tion in these families.
In family IV, a novel AT insertion in exon 13 between
nucleotides 1610 and 1611 was also identified. The
resultant frameshift change leads to a premature termi-
nation codon shortly downstream of the insertion site.
The second mutation found in family V was another
unreported mutation. Patient V.I, her mother and half
sister, were found to bear an AT deletion (c.80_81delAT)
in a region of exon 2 in the N-terminal domain. This
deletion converts D27 into an alanine residue and leads
to a frame-shifting situation that causes a premature
stop codon (p.D27Afs*18).
The remaining mutations found in the patients that
we studied had been previously described elsewhere:
c.485 G>A [17], c.772 G>A [18], c.1176_1177dupAT
[19], c.1420 C>T [20] (Table 1). The second mutation
found in patient I.1 (c.485 G>A) is probably a de novo
alteration, as both brother and sister of the proband do
not carry this change. The father was deceased, so no
further investigations could be performed on the segre-
gation of this c.485 G>A change.
All the mutations reported here are shown in a sche-
matic CFI protein model based on Protein Data Base
accession 2XRC (Figure 3).
Discussion
As part of innate immunity, the complement system
plays an important role in the defense against pathogens,
especially in early childhood. Spontaneous and continu-
ous activation of the complement cascade [21] must be
tightly regulated by both fluid-phase and membrane-
bound inhibitors to prevent uncontrolled amplification
of C3 cleavage that may result in a state of acquired
severe C3 deficiency.
The C3 fragments generated by complement activation
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I.2 I.1 II.2 III.1 III.4 III.2 III.3 CFI II.1 II.3 IV.1 IV.4 IV.2 IV.3 V.1 V.3 V.2 V.4 
76 KDa 
Figure 1 Pedigrees and complement studies. A) Pedigrees of the families with CFI deficiency. Black symbols represent complete deficient of
CFI and half-filled symbols indicate partial deficiency. B) Western blot analysis of CFI in serum samples. C) Complement profiles: measurement of
C3, C4, CFB, CFH, CFI, C3NeF and CFHA plasma levels. Abbreviations used: NEG, negative. ND, not determined. CFB, Complement Factor B. CFH,
Complement Factor H. CFI, Complement Factor I. C3NeF, C3 Nephritic Factor. CFHA, Complement Factor H auto antibodies.
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tic cells via complement receptors), enhancement of anti-
gen solubility and immunogenicity, non-inflammatory
removal of cell debris and immune complexes by phago-
cytes and promotion of the inflammatory environment
required for correct immune response [2,5,22]. Deficiency
of Complement Factor I (CFI, OMIM*217030) is a very
rare primary immunodeficiency disease [23], inherited as
an autosomal recessive trait. Heterozygous CFI mutations
are associated with atypical haemolytic uremic syndrome
(aHUS) [20], a severe disorder characterized bythrombocytopenia, microangiopathic haemolytic anaemia
and acute renal failure.
Defective opsonization in these patients makes them
susceptible to recurrent pyogenic infections (Streptococ-
cus pneumoniae, Haemophilus influenzae, Neisseria
meningitidis) as well as to aseptic meningitis [12,24].
Furthermore, deregulation of the complement cascade
may result in autoimmune disease [22], vasculitis or glo-
merulonephritis [25].
Among the CFI deficient individuals reported here, five
out of seven homozygotes developed clinical symptoms
Table 1 Summary of the CFI mutations identified in the five families
Patients Genetic status cDNA ATG +1 Protein with signal peptide Exon Domain References
III.1, III.2, III.4 He c.266-?_536 + ?del - 2 - Not described
V.1, V.2, V.4 He c.80_81delAT p.D27Afs*18 2 N-terminal Not described
I.1 He c.485 G>A p.G162D 4 SRCR Le Quintrec M. et al. 2008 [17]





c.772 G>A p.A258T 5 LDLRA2 Vyse et al. 1996 [18]
I.1, I.2 He c.1176_1177dupAT p.W393Yfs*5 11 SP Baracho et al. 2003 [19]
III.1, III.3, III.4 He c.1420 C> T p.R474X 11 SP Fremaux-Bacchi et al. 2004 [20]
IV.1, IV.2, IV.4 He c.1610_1611insAT p.V537Vfs*2 13 SP Not described
Ho, Homozygote; He, Heterozygote; SRCR, Scavenger Receptor Cysteine Rich domain; LDLRA2, Class A low-density lipoprotein receptor domain 2; SP, Serine
Protease domain.
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zygous carriers, other authors have described symptoms
ranging from infections to aHUS [26,27]. To date, none of
the relatives with partial CFI deficiency in our series have
experienced symptoms.
At the present time, there is no specific therapy for
these patients except keeping tight control on their vac-
cination against common bacterial pathogens such as S.
pneumoniae, H. influenzae and N. meningitidis, and test-
ing their correct antibody production. Despite normal
polysaccharide antibody production in these patients,
antibody weaning is faster than in the common popula-
tion [28]. Furthermore, special care has to be taken to
prevent associated diseases (using prophylactic antibio-
tics if necessary) [3]. The main therapeutic goal is to
promote the synthesis of anti-capsular antibodies cap-
able of efficiently activating the classical pathway,
although plasma infusion may be used in cases of severe




Figure 2 Long range PCR. XL-PCR of a genomic fragment
spanning approximately 8Kb. Patient III.1, his mother (III.2) and
brother (III.4) are heterozygous for the exon 2 deletion. His father
(III.3) does not carry the deletion.Familial studies lead us to identify two homozygous
children in families III and IV without clinical evidences
of CFI deficiency. Their very early diagnoses and the
therapeutic precautions taken can most probably explain
the lack of clinical manifestations. Even so, we cannot
rule out the eventual onset of disease in such patients.
In this study, we aimed to show that in the presence of
suggestive pathology and marked, but not absolute, per-
manent C3 deficiency, screening of complement regula-
tors should be performed. Besides, determination of CFI
levels may discard other relatively frequent causes of C3
consumption (like C3NeF or CFH auto antibodies) and
thus can guide the clinician in diagnostic tasks. The pre-
sence of C3NeF can cause excessive C3 consumption,
but clinical signs associated with this autoantibody fit in
better with Dense Deposit Disease (DDD) and partial
lipodystrophy (PLD) [29,30]. Auto antibodies directed
against CFH can also decrease circulating C3 levels
while maintaining C4 concentration in its normal range
[31-33]. Moreover, functional studies have revealed that
autoantibodies provoke the same dysfunction in CFH as
mutations in its C-terminal domain, and there seems to
be a direct correlation between the extent of CFH dys-
function and the amount of CFH-autoantibody com-
plexes [34]. Recently, anti-CFI autoantibodies have been
described in aHUS, but their relationship with the devel-
opment of the disease remains uncertain [35]. We have
not tested the presence of anti-CFI antibodies in these 5
families, although this possibility could be explored in
cases in which CFI deficiency is suspected.
Complete C3 or CFH deficiency presents clinical out-
comes similar to those of CFI deficiency so that bio-
chemical and/or functional studies are needed to
distinguish among these deficiencies. Identification of
the underlying molecular defect can be accomplished
following the diagnostic algorithm depicted in Figure 4.
On the other hand, partial defect of C3, CFH or CFI is
a susceptibility factor to develop aHUS, one of the most
Figure 3 Schematic model of the CFI protein and gene. The protein domains, exon/intron gene structure and the mutations found in our
series are depicted.
Molecular study of 
complement defect 
(sequencing, MLPA)
C3NeF anti CFH auto 
antibodies




Low C3 and normal C4
quantification
C3Nef Haemolytic Assay 
CFH, CFI and CFB quantification 
Anti CFH quantification 
Uncontrolled AP activation 
and C3 consumption 
C3NeF antibody 
stabilizes the AP C3 
convertase 
(C3 consumption)
Anti CFH antibodies 
neutralize the regulatory 
activity of FH. 
Lack of complement 
activation 
Figure 4 Additional studies for a patient with low C3 (20-30% of normal expression) and normal C4: Alternative pathway of
complement activation.
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deregulation. When CFI deficiency has been established,
family studies are needed in order to predict the conse-
quences arising from the segregation of the mutated
allele in the family. Multiple concurrent factors, both
environmental and genetic, may be necessary in an indi-
vidual for disease manifestation of aHUS [36]. Environ-
mental factors are thought to initiate endothelium
damage, while genetic factors favour disease progression
[32]. Moreover, combined deficiencies of two or more
complement factors (structural o regulator) have also
been described, which adds complexity to these comple-
ment deficiencies. Furthermore, a genetic component
may also contribute to some typical, infectious HUS
cases [33].
Conclusions
Complement Factor I (CFI) is the major complement inhi-
bitor that degrades activated complement components
C3b and C4b in the presence of specific cofactors. Its
complete deficiency results in secondary complement
deficiency due to uncontrolled spontaneous alternative
pathway activation and causes susceptibility to infections.
To date, mutations in several CFI domains have been
described worldwide. Here, we report four novel muta-
tions and the first large gene deletion in the CFI locus.
We propose a general screening for this complement
immunodeficiency whenever suggestive clinical features
are present in the patient. C3 and C4 quantification are
available to most laboratories, thus guiding the clinician
at an early stage of the study (see Figure 4). Then, if the
results are related to an alternative pathway deficiency
with low C3 and normal C4, a multistep process may be
performed in a more specialized laboratory for the pre-
cise characterization of the defect at the molecular level.
Such diagnostic process should include complement
functional assays, protein quantification and auto anti-
body analysis.
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